🏛️ Verified NIH Record • Updated 2026-06-01
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment (NCT04617522)
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Gilead Sciences
🩺 Plain-English Summary (8th-Grade Level)
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
Who can join: Review the eligibility criteria below.
Location: Pacific Shores Medical Group — Long Beach, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Pacific Shores Medical Group — Long Beach, California
- Christiana Care Health Services — Newark, Delaware
- University of Maryland — Baltimore, Maryland
- NEXT Austin — Austin, Texas
- Oncology Consultants, P.A. — Houston, Texas
- The University of Texas M.D. Anderson Cancer Center — Houston, Texas
- Texas Liver Institute — San Antonio, Texas
- NEXT Oncology — San Antonio, Texas
- Institut Bergonie Medical Oncology — Bordeaux,
- Centre Leon Berard — Lyon,
- Institut de Cancerologie de l'Ouest (ICO) - Saint-Herblain — Saint-Herblain,
- Instituto Europeo di Oncologia — Milan,
- Istituto Nazionale Tumori IRCCS Fondazione G. Pascale — Naples,
- Institut Català d'Oncologia - L'Hospitalet de Llobregat — Barcelona,
- Hospital Universitario Virgen del Rocío — Seville,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.